Journal article
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Abstract
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 and PCV15 with those to 13-valent PCV (PCV13) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.). Antibody responses to two …
Authors
Kobayashi M; Farrar JL; Gierke R; Britton A; Childs L; Leidner AJ; Campos-Outcalt D; Morgan RL; Long SS; Talbot HK
Journal
MMWR Morbidity and Mortality Weekly Report, Vol. 71, No. 4, pp. 109–117
Publisher
Centers for Disease Control MMWR Office
DOI
10.15585/mmwr.mm7104a1
ISSN
0149-2195